Research · Sep 3, 2026
[BBIO] BridgeBio Pharma Thesis 2026: Attruby Launch Drives ATTR-CM Cardiology Revenue Inflection
BridgeBio Pharma Inc. (NASDAQ: BBIO) FY2025 revenue ~$425-510M (+250-330%) with adj. EPS ~-$2.50 to -$1.75 reflecting selected post-November 2024 ~$430M aggregate Attruby (acoramidis) approval (selected primary novel ATTR-CM transthyretin amyloid cardiomyopathy treatment) + selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue trajectory + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation under continued Founder + CEO Neil Kumar since 2015 (~10-year tenure as BridgeBio Pharma Founder + CEO). One of the world's leading clinical-stage biotechnology companies focused on genetic diseases + selected various rare diseases drug development. Founded 2015 as BridgeBio Pharma in Palo Alto California by Neil Kumar + selected various Third Rock Ventures partners + selected various Stanford University researchers (~10-year heritage); selected post-2015-2019 ~$1B+ aggregate venture capital funding; selected post-June 2019 NASDAQ listing IPO (~$348M aggregate raised); selected post-November 2024 ~$430M aggregate Attruby FDA approval for ATTR-CM. Headquartered in Palo Alto California; ~700+ employees globally with ~$425-510M revenue. Two primary product + clinical segments: Attruby (acoramidis) Commercial (~85%+ ~$365-435M), Pipeline + Clinical (~15% ~$60-75M). Geographic mix: US ~95%+ + International ~5%. Attruby + ATTR-CM cardiology launch: post-November 2024 ~$430M aggregate Attruby FDA approval; selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue + ~$1.0B+ aggregate FY2026 revenue expectation; selected primary US ATTR-CM treatment + selected various Pfizer Vyndaqel + Vyndamax + Alnylam Amvuttra competitive positioning. Pipeline + clinical development: BBO-11273 + BBO-10203 + RAS oncology + achondroplasia + encaleret hypoparathyroidism + ADH1 + selected various early-stage pipeline. Founder + CEO Neil Kumar since 2015 (~10-year tenure); CFO Brian Stephenson. Capital + cash position + GAAP profitability: ~$1.2B+ aggregate cash + investments balance; ~$200-300M aggregate net debt position; selected post-2024 ~$300M aggregate convertible debt + ~$300M+ aggregate royalty financing; selected pathway to GAAP profitability inflection FY2026-2027 driven by Attruby launch. FY2026 thesis: Attruby + ATTR-CM cardiology launch + Pipeline + clinical development + ~$1.0B+ aggregate FY2026 Attruby revenue expectation + ~$1.0-1.2B aggregate cash + investments balance + selected pathway to GAAP profitability inflection FY2026-2027 + selected potential post-2024 capital return optionality. Risks: Attruby commercialization sustainability, Pfizer Vyndaqel + Vyndamax + Alnylam Amvuttra competition, GAAP profitability inflection trajectory, clinical pipeline risk, US payer + international reimbursement risk.